Year Founded
2021
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Mirai Bio General Information
Platform company focused on developing end-to-end genetic medicine development capabilities using machine intelligence for optimizing delivery, design and manufacturing
Drug Pipeline
No pipeline data available
Key Partnerships
Mirai Bio Funding
Deal Type | Date | Amount | Status | Stage |
---|
To view Mirai Bio's complete valuation and funding history, request access »
Mirai Bio Investors
Flagship Pioneering (initial commitment of $50 million)
Investor Type: Venture Capital
Holding: Minority